% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • richeydouglas Apr 20, 2012 12:56 AM Flag


    According to the New York Times.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • quit spamming up the board with your Mississippi Math, face the facts, BSX is a POS!

      "US CRM sales were down 14% this quarter, worse than St. Jude's (-7%) performance (and Medtronic (MDT ) won't report for a while). ICD revenue fell 12% (St. Jude's fell 2%), indicating that BSX continues to lose share despite some controversy with St. Jude's leads."

      "Global sales of coronary stent system (within Interventional Cardiology) at $387 million declined 5.8% due to disappointing performance from both drug-eluting stents (“DES”) that declined 4.2% to $363 million and bare-metal stents that plunged 20% to $24 million."

      • 1 Reply to pet_detective78
      • Pet detective

        For someone accusing someone else of spamming up the board. You sure have posted this message many many times.

        This post that you keep posting are facts from the articles that you have cited. The point I would like to make is all that was baked into the stock price before the conference call. Everything you are citing was within guidance from the Q4 2011 conference call that occurred in late Jan. 2012. What will drive a stock price will be a surprise one way or the other. Everything you are posting was not a surprise.

        The following is the guidance that was giving for Q1 2012. This is from the transcript from that conference call. (Cut and paste)

        Now turning to Q1 2012, we expect consolidated revenues to be in the range of $1,825,000,000 to $1.9 billion. If current foreign exchange rates hold constant, the headwind from FX should be approximately $10 million or 50 basis points relative to Q1 2011.

        On a constant currency basis, we expect consolidated Q1 sales to be in the range of flat to down 5%. On a worldwide basis, we expect DES revenue to be in the range of $365 million to $385 million and CRM revenue to be in the range of $480 million to $510 million in the first quarter. For the first quarter, adjusted earnings per share is expected to be in the range of $0.11 to $0.14 per share on an adjusted basis, and reported GAAP EPS is expected to be in the range of $0.02 to $0.05 per share.

        That's it for guidance.

        On a few of the facts of guidance versus what actually happened it was actually a beat as opposed to just in line with estimates for Q1 2012.

        So like Richey said anyway you slice it

        It was a good quarter for BSX

        Oh and guidance for Q2 2012. For the first time in a long time the high end of the current guidance range is growth for the company of 1 percent as opposed to flat (previous guidance of previous quarters)as the high end of guidance.
        And also a clear return to growth in the second half of 2012

    • richeydouglas Apr 23, 2012 12:18 PM Flag

      markets are down huge today on global economic data. BSX off a little. This must mean that investors are not as willing to sell BSX at these levels.

23.73+0.02(+0.08%)Sep 26 4:02 PMEDT